Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

Rheumatoid arthritis is a chronic autoimmune disease that affects millions of people worldwide. This disease prompts the ...

Tom Nolan reviews this week’s research GLP-1 receptor agonists, now widely used for diabetes, cardiovascular disease, and weight loss, seem to be as effective for these indications regardless of age, ...

RA can affect your lifespan in various ways related to cardiovascular disease, lung disease, infection, depression, and ...

Up to 30% of children with juvenile arthritis develop uveitis, an eye inflammation that can damage vision. New research highlights immune cells as treatment targets.

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

The FDA will review the supplemental Biologics License Application for tildrakizumab for the treatment of adults with active PsA.

The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...

Ilumya has secured marketing authorisations from more than 55 health authorities worldwide.

Advantage plans do a better job than standalone Part D policies, albeit with important gap ...

BITS Pilani's new nanomedicine gel shows promising preclinical results for rheumatoid arthritis treatment, enhancing drug delivery and reducing inflammation.

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...